Our November issue is now online. Stay tuned for some highlights.
Register for content alerts https://t.co/PgQbd2OXjq

among other exciting research
Table of contents: https://t.co/SeEu2hfwdT

14 15

The October issue of is here!

Including original research on end-of-life care, and and much more!

Read it here: https://t.co/A6eCrP5bkJ

17 33

Our November issue is now live. Read it here:
https://t.co/w5aMWwOWSL
for articles on neuroendocrine tumours, and more

12 34

Our May issue is now online! Including pieces on and articles on refugees, cholangiocarcinoma, cancer drug pricing, & more
Read it here: https://t.co/w5aMWwOWSL

3 16

squamous with pressing need for better outcomes. Combination of afatinib and pembrolizumab discussed by - unfortunately not well tolerated. 40% with G3 AEs.

3 15

and the most widely studied substrates in the field of have different advantages and disadvantages, and may be complementary.

📚Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages

6 16

Interesting data from with pembrolizumab in locally advanced after chemoradiation. Current standard here remains durvalumab but this appears consistent with what we would expect.

8 21